Aliases & Classifications for End Stage Renal Disease

MalaCards integrated aliases for End Stage Renal Disease:

Name: End Stage Renal Disease 12 15
Chronic Kidney Disease Stage 5 70
End-Stage Kidney Disease 12
End Stage Renal Failure 12
End-Stage Renal Disease 6
Kidney Failure, Chronic 70

Classifications:



External Ids:

Disease Ontology 12 DOID:783
ICD9CM 34 585.6
UMLS 70 C0022661 C2316810

Summaries for End Stage Renal Disease

Disease Ontology : 12 A chronic kidney disease is characterized by non-functioning kidneys, as the final stage in chronic kidney disease.

MalaCards based summary : End Stage Renal Disease, also known as chronic kidney disease stage 5, is related to microvascular complications of diabetes 2 and microvascular complications of diabetes 1, and has symptoms including cloudy (hemodialysis) (peritoneal) dialysis effluent An important gene associated with End Stage Renal Disease is PKD1 (Polycystin 1, Transient Receptor Potential Channel Interacting), and among its related pathways/superpathways is Primary Focal Segmental Glomerulosclerosis FSGS. The drugs Acetylcysteine and Olmesartan have been mentioned in the context of this disorder. Affiliated tissues include kidney, endothelial and pancreas, and related phenotypes are Decreased replication of vaccinia virus (VACV) and cardiovascular system

Wikipedia : 73 Kidney failure, also known as end-stage kidney disease, is a medical condition in which the kidneys are... more...

Related Diseases for End Stage Renal Disease

Diseases related to End Stage Renal Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1210)
# Related Disease Score Top Affiliating Genes
1 microvascular complications of diabetes 2 33.5 EPO ACE
2 microvascular complications of diabetes 1 33.0 VEGFA HFE EPO
3 familial nephrotic syndrome 32.8 CD2AP APOL1 ACTN4
4 focal segmental glomerulosclerosis 5 32.8 CD2AP APOL1 ACTN4
5 type 1 diabetes mellitus 32.7 VEGFA SOD2 PVT1 PON1 IL1RN ACE
6 microvascular complications of diabetes 5 32.7 VEGFA SOD2 PON1 ACE
7 polycystic kidney disease 1 with or without polycystic liver disease 32.6 PKD1 NEK8 INVS ACE
8 alport syndrome 32.6 VEGFA PKD1 MYH9 CFH CD2AP APOL1
9 focal segmental glomerulosclerosis 1 32.5 CD2AP APOL1 ACTN4
10 focal segmental glomerulosclerosis 2 32.5 CD2AP ACTN4
11 nephronophthisis 2 32.4 PKD1 NEK8 INVS
12 polycystic kidney disease 2 with or without polycystic liver disease 32.4 PKD1 NEK8 INVS
13 glomerulonephritis 32.4 MYH9 CFH APOL1 ACE
14 uremia 32.4 PON1 EPO ACE
15 focal segmental glomerulosclerosis 6 32.4 CD2AP ACTN4
16 polycystic kidney disease 4 with or without polycystic liver disease 32.3 PKD1 NEK8 INVS
17 proteinuria, chronic benign 32.2 VEGFA CD2AP APOL1 ACTN4 ACE
18 vascular disease 32.2 VEGFA THBD PON1 EPO ACE
19 peripheral vascular disease 32.1 VEGFA THBD EPO ACE
20 cakut 32.1 GATA3 APOL1 ACE
21 polycystic kidney disease 31.9 VEGFA PKD1 NEK8 INVS EPO CD2AP
22 atherosclerosis susceptibility 31.9 VEGFA THBD PON1 ACE
23 sleep apnea 31.9 VEGFA EPO ACE
24 deficiency anemia 31.9 PON1 HFE EPO CFH ACE
25 focal segmental glomerulosclerosis 31.8 PON1 MYH9 CD2AP APOL1 ACTN4 ACE
26 nephrotic syndrome 31.7 PON1 MYH9 CD2AP APOL1 ACTN4 ACE
27 iga glomerulonephritis 31.7 CFH CD2AP ACE
28 ischemia 31.7 VEGFA SOD2 PON1 IL1RN EPO ACE
29 glomerular disease 31.7 CD2AP ACTN4 ACE
30 neuropathy 31.6 VEGFA SOD2 IL1RN HFE EPO ACE
31 chronic kidney disease 31.5 VEGFA THBD RNLS PON1 PKD1 MYH9
32 myocardial infarction 31.4 VEGFA THBD PON1 HFE EPO CFH
33 systemic lupus erythematosus 31.4 VEGFA THBD PON1 IL1RN GATA3 APOL1
34 hypertension, essential 31.4 VEGFA THBD SOD2 RNLS PON1 PKD1
35 malignant hypertension 31.4 THBD CFH ACE
36 lipoprotein quantitative trait locus 31.4 VEGFA THBD PON1 IL1RN ACE
37 heart disease 31.4 VEGFA THBD SOD2 PON1 IL1RN HFE
38 diabetes mellitus 31.4 VEGFA THBD SOD2 PVT1 PON1 IL1RN
39 respiratory failure 31.4 VEGFA THBD IL1RN EPO ACE
40 thrombotic microangiopathy 31.3 VEGFA THBD
41 stroke, ischemic 31.3 THBD SOD2 PON1 ACE
42 eclampsia 31.3 VEGFA THBD ACE
43 antiphospholipid syndrome 31.3 THBD PON1 CFH
44 type 2 diabetes mellitus 31.3 VEGFA THBD SOD2 PVT1 PON1 MYH9
45 renal artery disease 31.2 EPO APOL1 ACE
46 hypertensive encephalopathy 31.2 VEGFA EPO ACE
47 kidney disease 31.1 VEGFA THBD RNLS PON1 PKD1 NEK8
48 macular retinal edema 31.1 VEGFA CFH ACE
49 diabetic neuropathy 31.1 VEGFA SOD2 PON1 EPO ACE
50 thrombocytopenia 31.1 THBD MYH9 IL1RN GATA3 EPO CFH

Graphical network of the top 20 diseases related to End Stage Renal Disease:



Diseases related to End Stage Renal Disease

Symptoms & Phenotypes for End Stage Renal Disease

UMLS symptoms related to End Stage Renal Disease:


cloudy (hemodialysis) (peritoneal) dialysis effluent

GenomeRNAi Phenotypes related to End Stage Renal Disease according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased replication of vaccinia virus (VACV) GR00362-A 8.62 CFH THBD

MGI Mouse Phenotypes related to End Stage Renal Disease:

46 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.41 ACE ACTN4 CD2AP CFH EPO GATA3
2 homeostasis/metabolism MP:0005376 10.32 ACE ACTN4 ALMS1 CD2AP CFH EPO
3 cellular MP:0005384 10.31 ACTN4 ALMS1 EPO GATA3 HFE IL1RN
4 growth/size/body region MP:0005378 10.31 ACE ACTN4 ALMS1 CD2AP CFH GATA3
5 hematopoietic system MP:0005397 10.31 ACE ACTN4 ALMS1 CD2AP CFH EPO
6 immune system MP:0005387 10.22 ACE ACTN4 ALMS1 CD2AP CFH EPO
7 embryo MP:0005380 10.11 ACE ACTN4 EPO GATA3 INVS MYH9
8 digestive/alimentary MP:0005381 10.08 ACTN4 GATA3 HFE INVS NEK8 PKD1
9 mortality/aging MP:0010768 10.03 ACE ACTN4 CD2AP CFH EPO GATA3
10 liver/biliary system MP:0005370 9.96 ACE ACTN4 ALMS1 EPO HFE INVS
11 nervous system MP:0003631 9.73 ACE ACTN4 ALMS1 CFH GATA3 HFE
12 renal/urinary system MP:0005367 9.44 ACE ACTN4 ALMS1 CD2AP CFH GATA3

Drugs & Therapeutics for End Stage Renal Disease

Drugs for End Stage Renal Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 539)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
2
Olmesartan Approved, Investigational Phase 4 144689-24-7, 144689-63-4 130881 158781
3
Candesartan cilexetil Approved Phase 4 145040-37-5 2540
4
Irbesartan Approved, Investigational Phase 4 138402-11-6 3749
5
Digoxin Approved Phase 4 20830-75-5 30322 2724385
6
Peginterferon alfa-2b Approved Phase 4 99210-65-8, 215647-85-1
7
Capsaicin Approved Phase 4 404-86-4 1548943
8
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
9
Ursodeoxycholic acid Approved, Investigational Phase 4 128-13-2 31401
10
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603
11
Enalaprilat Approved Phase 4 76420-72-9 6917719
12
Enalapril Approved, Vet_approved Phase 4 75847-73-3 5362032 40466924
13
Febuxostat Approved Phase 4 144060-53-7 134018
14
Nadroparin Approved, Investigational Phase 4
15
Alprostadil Approved, Investigational Phase 4 745-65-3 149351 5280723
16
Lactitol Approved, Investigational Phase 4 585-86-4 157355
17
Telavancin Approved Phase 4 372151-71-8
18
tannic acid Approved Phase 4 1401-55-4
19
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
20
Ranolazine Approved, Investigational Phase 4 142387-99-3, 95635-55-5 56959
21
Ribavirin Approved Phase 4 36791-04-5 37542
22
Levoleucovorin Approved, Investigational Phase 4 68538-85-2 149436
23
Sirolimus Approved, Investigational Phase 4 53123-88-9 6436030 5284616
24
Peginterferon alfa-2a Approved, Investigational Phase 4 198153-51-4 5360545
25
Basiliximab Approved, Investigational Phase 4 152923-56-3, 179045-86-4
26
Donepezil Approved Phase 4 120014-06-4 3152
27
alemtuzumab Approved, Investigational Phase 4 216503-57-0
28
Everolimus Approved Phase 4 159351-69-6 6442177 70789204
29
Remifentanil Approved Phase 4 132875-61-7 60815
30
Thiopental Approved, Vet_approved Phase 4 76-75-5 3000715
31
Desflurane Approved Phase 4 57041-67-5 42113
32
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
33
Rivaroxaban Approved Phase 4 366789-02-8
34
Darbepoetin alfa Approved, Investigational Phase 4 209810-58-2, 11096-26-7
35
Atorvastatin Approved Phase 4 134523-00-5 60823
36
Eplerenone Approved Phase 4 107724-20-9 443872 150310
37
Pentoxifylline Approved, Investigational Phase 4 6493-05-6 4740
38
Taurolidine Approved, Investigational Phase 4 19388-87-5
39
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
40
Allopurinol Approved Phase 4 315-30-0 2094
41
Ertapenem Approved, Investigational Phase 4 153832-46-3 150610
42
Argatroban Approved, Investigational Phase 4 74863-84-6 152951
43
Liraglutide Approved Phase 4 204656-20-2 44147092
44
Amlodipine Approved Phase 4 88150-42-9 2162
45
Bisoprolol Approved Phase 4 66722-44-9 2405
46
Colchicine Approved Phase 4 64-86-8 6167 2833
47
Insulin aspart Approved Phase 4 116094-23-6 16132418
48
Nifedipine Approved Phase 4 21829-25-4 4485
49
Nystatin Approved, Vet_approved Phase 4 1400-61-9 11953884
50
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999

Interventional clinical trials:

(show top 50) (show all 1714)
# Name Status NCT ID Phase Drugs
1 Simvastatin Effect on Endothelium Dependent Venodilation in Chronic Renal Failure Patients Treated by Peritoneal Dialysis Unknown status NCT00291863 Phase 4 Simvastatin
2 The Effect of Far Infrared (FIR) Therapy on Access Flow of Arteriovenous (AV) Fistula, Echocardiographic Parameters and Endothelial Function in Patients With End Stage Renal Disease Unknown status NCT01138254 Phase 4
3 The Impact of Conventional Hemodialysis, High Flux Hemodialysis and Hemodiafiltration on Adiponectin, Vascular Function and Clinical Prognosis Unknown status NCT00155363 Phase 4
4 The Determinants of the Effectiveness of the Use of Furosemide in Patients on Dialysis Unknown status NCT01815892 Phase 4 Withdrawal of furosemide;furosemide administration
5 The Association Between Body Composition and Biomarkers in Hemodialysis Patients Unknown status NCT01103167 Phase 4
6 The Effect of Ferric Citrate on Inflammation and Lipid Levels in Patients on Hemodialysis Unknown status NCT02661295 Phase 4 Ferric Citrate
7 Effects of On-Line Hemodiafiltration(HDF) on Endothelial Dysfunction in Chronic Hemodialysis Patients Unknown status NCT00532597 Phase 4
8 A Prospective Randomized, Double-Blind Parallel Group Trial To Assess The Efficacy And Safety Of Intravenous Dextrose 5% Solution Compare With Normal Saline (Standard Care) In Rinsing During Haemodialysis In Subjects With End Stage Renal Failure (ESRF) With Respect To Systolic Blood Pressure Control Over 3 Months Period. Unknown status NCT02590081 Phase 4 Dextrose 5%;normal saline
9 Marinobufagenin as a Target for DIGIBIND in Hypertensive Patients With End-stage Renal Disease Unknown status NCT00852787 Phase 4 Digoxin immune fab;Placebo
10 A comParison on Platelet Resistance With Ticagrelor or Standard-Dose Clopidogrel Study Among SeVerE Chronic Kidney Disease/ End-Stage-Renal-Disease Patients With Recent Acute Coronary Syndrome. Unknown status NCT02459288 Phase 4 Clopidogrel first;Ticagrelor first
11 Hypervolemia and Treatment Guided by Bioimpedance in End Stage Renal Disease Patients in Zonguldak (Prospective Study) Unknown status NCT01468363 Phase 4
12 The Efficacy and Safety of Niacin on Hyperphosphatemia in End Stage Renal Disease Patients Undergoing Haemodialysis Unknown status NCT03163576 Phase 4 Niacin;Phosphate Binder
13 A Comparative Study of Dexmedetomidine and Propofol As Sole Sedative Agent for Patients With End-Stage Renal Disease Undergoing Arteriovenous Fistula Surgery Unknown status NCT02447796 Phase 4 Propofol;Dexmedetomidine
14 A Phase-IV Study Comparing Standard Release Tacrolimus (Prograf) vs Prolonged-release Tacrolimus (Advagraf) Monotherapy as Maintenance Immunosuppression After Induction With Alemtuzumab in Kidney Transplantation Unknown status NCT00807144 Phase 4 Tacrolimus (Kidney transplant maintenance immunosuppression);Kidney transplant maintenance immunosuppression
15 The Role of Qutenza (Topical Capsaicin 8%) in Treating Neuropathic Pain From Critical Ischaemia in Patients With End-stage Renal Failure Unknown status NCT01704339 Phase 4 QUTENZA
16 Inspiratory Muscle Training in Patients With End Stage Renal Failure: a Randomized Controlled Trial Unknown status NCT01347775 Phase 4
17 A Randomized Prospective Trial of N-acetyl Cystein in Patients With Peritoneal Dialysis Unknown status NCT01111422 Phase 4 N-acetylcysteine
18 Effect of Ursodeoxycholic Acid on Peritoneal Function in Patients on Peritoneal Dialysis Unknown status NCT02338635 Phase 4 Ursodeoxycholic Acid
19 Clinical Trial Simulation Using ODE/PDE Hemodialysis Model for Quantifying Oxycodone's Removal in End-Stage Kidney Disease Unknown status NCT02452437 Phase 4 Oxycodone
20 Open Randomized Phase IV Study on Intravenous Iron in Anemic Patients With Chronic Kidney Disease Unknown status NCT00204256 Phase 4 Iron sucrose
21 Clinical Trial, Open, Parallel Groups , Value the Antiproteinuric Effects From Vitamin D Derivatives in Patient With Chronic Kidney Illness and the Lack of Vitamin D Unknown status NCT01442272 Phase 4 Hidroferol®;Paricalcitol: Zemplar®;Habitual medication
22 Interstitial Fibrosis in Protocol Biopsies of Renal Allografts: A Prospective, Randomised Trial of Sirolimus Versus Cyclosporine.(Fibrasic) Unknown status NCT00493194 Phase 4 sirolimus;cyclosporine;daclizumab
23 The Effects of AST-120 on Endothelial Dysfunction in Patients With Chronic Kidney Disease Unknown status NCT01157260 Phase 4 Kremezin
24 Pulse Wave Velocity, Pulse Wave Morphology and Blocking of the Reninangiotensin System in Patients With Chronic Kidney Disease: An Interventional and Methodological Study Unknown status NCT00235287 Phase 4 Candesartan and enalapril;candesartan and enalapril;candesartan and enalapril;candesartan and enalapril
25 Hemocontrol's Effectiveness in a RAndomized Controlled Trial on the Reduction of Cardiovascular Long-term EventS Unknown status NCT01515878 Phase 4
26 Renal Toxicity of Iodixanol and Iopromide in Patients With Renal Dysfunction-a Multicentre, Single Blind, Randomized Controlled, Prospective Trial Unknown status NCT01580046 Phase 4 iodixanol;iopromide
27 Impact of a Mineralocorticoid Receptor Antagonist on Chronic Histological Changes in Renal Allograft Unknown status NCT01510795 Phase 4 spironolactone
28 Low-molecular Heparin Infusion as Anticoagulation for Nocturnal Home Hemodialysis Unknown status NCT02957877 Phase 4 Nadroparin;Unfractionated heparin
29 Effects of an Exercise Program in Patients With Hypertensive Chronic Kidney Disease: a Randomized Clinical Trial Unknown status NCT01155128 Phase 4
30 NAC in Preventing CIN in CRF Patients Who Need Enhanced CT Scan in ED Unknown status NCT00501475 Phase 4 NAC Bicarbonate
31 Providing Intravenous Paricalcitol Treatment to the Sick and Poor Chronic Hemodialysis Patients With Severe Secondary Hyperparathyroidism Resistant to Existing Vitamin D Analogs Unknown status NCT03023748 Phase 4 Intravenous Paricalcitol
32 The Effects of Acetylcysteine on Alleviating Damage of Oxidative Stress in Hemodialysis Patients Unknown status NCT00247507 Phase 4 acetylcysteine
33 Evaluation of Nail Fold Microcirculation and Interventional Therapy in Patients With Chronic Renal Failure Unknown status NCT03682952 Phase 4 Alprostadil Injection;Beraprost sodium tablets
34 Effects of Cholecalciferol on Osteoprotegerin Levels and Other Clinical Outcomes in Chronic Kidney Disease Patients on Peritoneal Dialysis: a Randomized Controlled Trial Unknown status NCT02598635 Phase 4 Cholecalciferol;Placebo
35 the Effect of Calcium Dobesilate on Non Dialysis Patients With Chronic Renal Failure Unknown status NCT03427944 Phase 4 Calcium Dobesilate group;Conventional Treatment group
36 Study on the Effect of Hyperuricaemia on Chronic Renal Disease and Intervention Unknown status NCT03425708 Phase 4 20mg Febuxostat;40mg Febuxostat
37 Phase 4 Study of Alprostadil Prevent Contrast Induced Nephropathy in Patients Receiving a Cardiac Catheterization Unknown status NCT01722513 Phase 4 Alprostadil ﹠control
38 Immunosuppression in Renal Transplantation in The Elderly: Time to Rethink. - nEverOld Study Unknown status NCT01631058 Phase 4 Everolimus
39 Effect of Hydration With Sodium Bicarbonate for Long-Term Clinical Outcomes in Patients With Chronic Kidney Disease Undergoing an Emergent Coronary Procedure Unknown status NCT00716001 Phase 4 N-acetylcysteine
40 Renoprotection by Combining Pentoxifylline and Angiotensin Blockade in Chronic Kidney Disease Unknown status NCT01377285 Phase 4 ARB;Pentoxifylline;Placebo (for Pentoxifylline)
41 A Pilot Study to Treat Patients With Chronic HCV Genotype 1 and ESRD Receiving Hemodialysis and Naïve to Prior HCV Therapy With Peginterferon Alfa-2b, the Maximally Tolerated Ribavirin Dose and Boceprevir Unknown status NCT01731301 Phase 4 Ribavirin;Peginterferon;Boceprevir
42 Randomized, Open Label, Controlled Clinical Trial of Egg Albumin-Based Protein Supplement Versus Renal Specific Oral Supplement in Hemodialysis Patients Unknown status NCT01981083 Phase 4
43 Upstream Use of Aliskiren in Hypertensive Haemodialysis Patients: Effects on Cardiovascular Outcomes Unknown status NCT01635387 Phase 4 aliskiren
44 Effect of Dialysis on the Pharmacokinetics of Telavancin in Patients With Chronic Kidney Disease Stage 5 Completed NCT02392208 Phase 4 Telavancin
45 Pharmacokinetics of Single-Dose Oral Ranolazine in Hemodialysis Patients Completed NCT01435174 Phase 4 Ranolazine
46 Comparison of Post-dilution On-line Hemodiafiltration and Hemodialysis (TURKISH HDF STUDY) Completed NCT00411177 Phase 4
47 Effects of Strict Volume Control in Hypertensive Hemodialysis Patients on Cardiac Structure and Chronic Inflammation: a Randomised, Prospective and Controlled Study Completed NCT00307463 Phase 4
48 Multiple Interventions Related to Dialysis Procedures in Order to Reduce Cardiovascular Morbidity and Mortality in Hemodialysis Patients: Prospective, Randomized, Controlled Study Completed NCT00295191 Phase 4
49 Effect of Arterial pH on N-balances of Patients Undergoing Automated Peritoneal Dialysis Completed NCT00586131 Phase 4 ammonium chloride or sodium citrate/citric acid;Sodium citrate/citratic acid
50 Streptococcus Pneumoniae Colonization and Immunogenicity of 13-valent Conjugate Pneumococcal Vaccine in Patients 50 Years or Older With End Stage Renal Disease on Dialysis. Completed NCT01974817 Phase 4

Search NIH Clinical Center for End Stage Renal Disease

Inferred drug relations via UMLS 70 / NDF-RT 51 :


Aluminum carbonate
basic aluminum carbonate gel
Bumetanide
calcium acetate
Calcium Carbonate
CALCIUM CARBONATE 1 g in 1 g ORAL POWDER
Calcium gluceptate
Cholecalciferol
Dihydrotachysterol
dihydroxyaluminum sodium carbonate
Ethacrynate Sodium
Ethacrynic Acid
Furosemide
magaldrate
Magnesium Hydroxide
MILK OF MAGNESIA
torsemide

Genetic Tests for End Stage Renal Disease

Anatomical Context for End Stage Renal Disease

MalaCards organs/tissues related to End Stage Renal Disease:

40
Kidney, Endothelial, Pancreas, Bone, Neutrophil, Skin, Bone Marrow

Publications for End Stage Renal Disease

Articles related to End Stage Renal Disease:

(show top 50) (show all 30021)
# Title Authors PMID Year
1
Whole-genome sequencing of patients with rare diseases in a national health system. 6
32581362 2020
2
Specific alterations in gut microbiota in patients with chronic kidney disease: an updated systematic review. 61
33406960 2021
3
The role of discoidin domain receptor 2 in the renal dysfunction of alport syndrome mouse model. 61
33706638 2021
4
Hematuria was a high risk for renal progression and ESRD in immunoglobulin a nephropathy: a systematic review and meta-analysis. 61
33685345 2021
5
Effect of galectin-3 in the pathogenesis of arteriovenous fistula stenosis formation. 61
33757402 2021
6
The effect of hyperkalemia and long inter-dialytic interval on morbidity and mortality in patients receiving hemodialysis: a systematic review. 61
33478329 2021
7
Association between atherosclerotic cardiovascular diseases risk and renal outcome in patients with type 2 diabetes mellitus. 61
33685340 2021
8
Approach to stable angina in patients with advanced chronic kidney disease. 61
33767062 2021
9
Increased lipoxygenase and decreased cytochrome P450s metabolites correlated with the incidence of diabetic nephropathy: Potential role of eicosanoids from metabolomics in type 2 diabetic patients. 61
33605471 2021
10
Antibody subtypes and titers predict clinical outcomes in ANCA-associated vasculitis. 61
33585954 2021
11
Molecular pathophysiology of acute kidney injury: The role of sirtuins and their interactions with other macromolecular players. 61
32989772 2021
12
Targeting optimal PD management in children: what have we learned from the IPPN registry? 61
32458134 2021
13
Rapid Electronic Capturing of Patient-Reported Outcome Measures in Older Adults With End-Stage Renal Disease: A Feasibility Study. 61
32935548 2021
14
Parathyroidectomy for tertiary hyperparathyroidism after second kidney transplantation: a case report. 61
33079356 2021
15
Surgical OFF-LOADING of the diabetic foot. 61
33717955 2021
16
Two novel nomograms for predicting the risk of hospitalization or mortality due to COVID-19 by the naïve Bayesian classifier method. 61
33599308 2021
17
Sarcomatoid renal cell carcinoma with autosomal dominant polycystic kidney disease: a case report and literature review. 61
33064294 2021
18
Neurophysiological control of urinary bladder storage and voiding-functional changes through development and pathology. 61
32415328 2021
19
Extensive bilateral renal metastases of non-small cell lung carcinoma caused acute kidney injury resulting in end-stage renal disease. 61
33058004 2021
20
Association Between Serum Albumin Level and All-Cause Mortality in Patients With Chronic Kidney Disease: A Retrospective Cohort Study. 61
32958160 2021
21
Recent advances in drug discovery for diabetic kidney disease. 61
33003971 2021
22
Evaluation of the Quality of Life and Health-Related Quality of Life of Patients With End-Stage Kidney Disease Resulting From Kidney Transplantation Using the Kidney Disease Quality of Life-Short Form and EuroQOL-5 Dimension-5 Level Questionnaires. 61
33303208 2021
23
Comparison of the health-related quality of life of end stage kidney disease patients on hemodialysis and non-hemodialysis management in Uganda. 61
33794849 2021
24
Association between dynapenic abdominal obesity and inflammatory profile in diabetic older community-dwelling patients with end-stage renal disease. 61
33460716 2021
25
Standardising clinical outcomes measures for adult clinical trials in Fabry disease: A global Delphi consensus. 61
33642210 2021
26
Toll-like receptor 4: An attractive therapeutic target for acute kidney injury. 61
33548286 2021
27
Renal outcomes and blood pressure patterns in diabetic and nondiabetic individuals at high cardiovascular risk. 61
33560052 2021
28
Renal Transplantation Improves Erectile Function in Patients with End-Stage Renal Disease: A Systematic Review and Meta-Analysis. 61
33320719 2021
29
Sofosbuvir and Velpatasvir combination is safe and effective in treating chronic hepatitis C in end-stage renal disease on maintenance haemodialysis. 61
33025685 2021
30
Ocular manifestations in renal allograft recipients: An Indian perspective. 61
33727456 2021
31
Safety outcomes with high-dose daptomycin in patients with acute kidney injury and/or end-stage renal disease. 61
33016513 2021
32
Association of platelet-to-lymphocyte ratio with kidney clinicopathologic features and renal outcomes in patients with diabetic kidney disease. 61
33524800 2021
33
LCC18, a benzamide-linked small molecule, ameliorates IgA nephropathy in mice. 61
33373038 2021
34
Urinary adiponectin excretion is an early predictive marker of the decline of the renal function in patients with diabetes mellitus. 61
33558151 2021
35
Nanomedicine in the treatment of diabetic nephropathy. 61
33677997 2021
36
Correlation between serum carnosinase concentration and renal damage in diabetic nephropathy patients. 61
33811534 2021
37
Mechanism of herbal medicine on hypertensive nephropathy (Review). 61
33537809 2021
38
Reconstruction of a Transplant Recipient's External Iliac Artery Using Donor's Inferior Vena Cava in Renal Transplantation: 2 Case Reports. 61
33004221 2021
39
Epidemiology of bloodstream infections in a Scottish haemodialysis population with focus on vascular access method. 61
33484781 2021
40
Evidence of Resilience in Kidney Donors: A New York Statewide Cohort Analysis. 61
33551185 2021
41
Soluble vascular endothelial growth factor receptor-1 as a novel marker of arteriovenous fistula stenosis in hemodialysis patients. 61
33155365 2021
42
[Applying Swanson`s Caring Theory to a Patient With End Renal Stage Disease Experiencing Hopelessness]. 61
33792024 2021
43
Dosage Adjustment for Ceftazidime in Pediatric Patients With Renal Impairment Using Physiologically Based Pharmacokinetic Modeling. 61
33556385 2021
44
Psychometric testing of the hemodialysis self-management instrument (HDSMI-18): A confirmatory factor analysis. 61
33794054 2021
45
Endothelin-targeted new treatments for proteinuric and inflammatory glomerular diseases: focus on the added value to anti-renin-angiotensin system inhibition. 61
32185491 2021
46
Lower serum albumin level is associated with increased risk of hospital admission and length of stay in hospital among incident hemodialysis patients by using overdispersed model. 61
32584500 2021
47
Comparison of the current renal staging, progression and response criteria to predict renal survival in AL amyloidosis using a Mayo cohort. 61
33428787 2021
48
Hepatitis B related dilemmas in the renal unit. 61
33155307 2021
49
Myocardial Iron Deficiency Quantification and Effective Cardiac Iron Management Strategy Exploration evaluated by Cardiac T2* Mapping in End-Stage Renal Disease Patients. 61
32402784 2021
50
Medical Management of Advanced Oxalate Nephropathy Secondary to Gastric Bypass Surgery. 61
33187632 2021

Variations for End Stage Renal Disease

ClinVar genetic disease variations for End Stage Renal Disease:

6
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 GATA3 NM_001002295.2(GATA3):c.1051-1G>C SNV Pathogenic 430696 rs112417755 GRCh37: 10:8115701-8115701
GRCh38: 10:8073738-8073738
2 PKD1 NM_001009944.3(PKD1):c.2079dup (p.Pro694fs) Duplication Pathogenic 374141 rs1057518923 GRCh37: 16:2165396-2165397
GRCh38: 16:2115395-2115396
3 ALMS1 NM_015120.4(ALMS1):c.1735del (p.Arg579fs) Deletion Likely pathogenic 374506 rs777476179 GRCh37: 2:73675386-73675386
GRCh38: 2:73448259-73448259
4 COL4A4 NM_000092.4(COL4A4):c.3055G>C (p.Glu1019Gln) SNV Uncertain significance 374041 rs1057518854 GRCh37: 2:227915788-227915788
GRCh38: 2:227051072-227051072
5 COL4A4 NM_000092.4(COL4A4):c.4217-15T>C SNV Uncertain significance 255039 rs200926310 GRCh37: 2:227877028-227877028
GRCh38: 2:227012312-227012312

Expression for End Stage Renal Disease

Search GEO for disease gene expression data for End Stage Renal Disease.

Pathways for End Stage Renal Disease

Pathways related to End Stage Renal Disease according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 10.67 MYH9 CD2AP ACTN4

GO Terms for End Stage Renal Disease

Cellular components related to End Stage Renal Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.91 VEGFA RNLS PON1 IL1RN EPO CFH
2 extracellular exosome GO:0070062 9.81 SOD2 PON1 PKD1 MYH9 IL1RN CFH
3 extracellular space GO:0005615 9.36 VEGFA THBD RNLS PON1 IL1RN HFE
4 ciliary inversin compartment GO:0097543 8.96 NEK8 INVS

Biological processes related to End Stage Renal Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 in utero embryonic development GO:0001701 9.67 VEGFA PKD1 MYH9 GATA3
2 response to hypoxia GO:0001666 9.62 VEGFA SOD2 EPO ACTN4
3 positive regulation of protein binding GO:0032092 9.58 PKD1 HFE ACE
4 monocyte differentiation GO:0030224 9.46 VEGFA MYH9
5 positive regulation of cellular component movement GO:0051272 9.43 VEGFA ACTN4
6 acute-phase response GO:0006953 9.33 IL1RN HFE EPO
7 positive regulation of peptidyl-tyrosine autophosphorylation GO:1900086 9.26 VEGFA ACE
8 kidney development GO:0001822 9.26 VEGFA PKD1 GATA3 ACE
9 lymph vessel morphogenesis GO:0036303 8.62 VEGFA PKD1

Molecular functions related to End Stage Renal Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 vascular endothelial growth factor receptor binding GO:0005172 8.62 VEGFA CD2AP

Sources for End Stage Renal Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....